Pharmaceutical stocks rebounded in a big way on the Zurich stock exchange in the wake of a tariff agreement reached by Pfizer in the United States. +Get the most important news from Switzerland in your inbox Long under pressure due to intentions to regulate drug prices in the US, companies are breathing a sigh of relief after US giant Pfizer was granted a three-year immunity against any prohibitive surcharges wielded by President Donald Trump in exchange for a series of concessions. + How pharma became Switzerland’s Achilles heel in the US Considering that this new business model could become the new normal, analysts welcome the decrease in uncertainty for the entire industry. Investors welcome the developments taking place and the effect on the stock exchange was not lacking: at midday on Wednesday Roche gained 5.3%, Novartis 2.4% and Lonza 0.8%. Pfizer's preparations will be sold more cheaply under the government's Medicaid health programme, Trump indicated at a press conference ...
